Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Significant Association of Metabolic Indices, Lipid Profile, and Androgen Levels with Prostate Cancer

  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To compare the metabolic indices, lipid profile, androgens, and prostate specific antigen between prostate cancer and BPH and between grades of prostate cancer in a cross-sectional study. Materials and Methods: The study enrolled 95 cases of prostate cancer and 95 cases of benign prostatic hyperplasia (BPH). Prostate gland volume was measured using transrectal ultrasound. We compared insulin, testosterone, dihydrotestosterone, prostate specific antigen levels and lipid profile between prostate cancer of different grades and BPH. Further, prostate cancer patients were classified into low grade and high grade. Unpaired t-test for normally distributed variables and Man-Whitney U test for non-normal variables were used to assess differences. Results: We found that prostate cancer patients had significantly higher levels of insulin, testosterone, PSA, cholesterol, triglycerides, low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) in comparison to their BPH counterparts. Higher levels of these parameters also correlated with a higher grade of the disease. Conclusions: We conclude that higher levels of insulin, testosterone, PSA, and cholesterol correlate with a higher risk of prostate cancer, and also with a higher grade of the disease.

Keywords

References

  1. Brawley OW (2003). Hormonal prevention of prostate cancer. Urol Oncol, 21, 2167-72.
  2. Burke JP, Rhodes T, Jacobson DJ, et al (2006). Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol, 164, 41-6. https://doi.org/10.1093/aje/kwj151
  3. Center MM, Jemal A, Lortet-Tieulent J, et al (2012). International variation in prostate cancer incidence and mortality rates. Eur Urol, 61, 1079-92. https://doi.org/10.1016/j.eururo.2012.02.054
  4. Clarke NW1, Hart CA, Brown MD (2009). Molecular mechanisms of metastasis in prostate cancer. Asian J Andro, 11, 57-67. https://doi.org/10.1038/aja.2008.29
  5. Clarke WN, Brown DM (2007). The Influence of Lipid Metabolism on Prostate Cancer Development and Progression: Is it Time for a Closer Look? Euro Urol, 52, 3-4. https://doi.org/10.1016/j.eururo.2007.04.039
  6. Dandona P, Weinstock R, Thus k, et al (1998). Tumor necrosis factor -$\alpha$, in sera of obese patients fall with weight loss. J Clin Endocrinol Metab, 83, 2907-10.
  7. Garfinkel L (1986). Overweight and mortality. Cancer, 58, 1826-29. https://doi.org/10.1002/1097-0142(19861015)58:8+<1826::AID-CNCR2820581407>3.0.CO;2-6
  8. Gillitzer R, Pahernik S, Hampelc (2005). Relationship between prostate cancer and serum dyslipidemia. Urology, 66, 13-14.
  9. Giovannucci E, Stampfer MJ, Krithivas K, et al (1997). The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A, 94, 3320-23. https://doi.org/10.1073/pnas.94.7.3320
  10. Girling JF, Whitaker HC, Mills IG (2007). Pathogenesis of prostate cancer and hormone refractory prostate cancer. Indian J Urol, 23, 35-42. https://doi.org/10.4103/0970-1591.30265
  11. Gupta A, Gupta S, Pavuk M, Roehrborn CG (2006). Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology, 68, 1198-205. https://doi.org/10.1016/j.urology.2006.09.034
  12. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D (1998). Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 3, 157-62.
  13. Hsing AW, Sakoda LC, Chua SC (2007). Obesity, metabolic syndrome, and prostate cancer. Amer J Clin Nutr, 86, 843-57.
  14. Jaradeen, N (2010). Breast cancer risk-factors and breast self examination practice among Jordanian women. Bahrain Med Bulletin, 32, 1
  15. Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C (2006). Serum lipid levels in benign prostatic hyperplasia. World J Urol, 24, 210-3. https://doi.org/10.1007/s00345-006-0062-6
  16. Long XJ, Lin S, Sun YN, Zheng ZF (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev, 13, 4097-100. https://doi.org/10.7314/APJCP.2012.13.8.4097
  17. McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13. https://doi.org/10.7314/APJCP.2012.13.1.001
  18. Mitropoulos D, Ploumidou K, Voulgari K (2003) Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl, 63, 2-20.
  19. Nandeesha H, Koner BC, Dorairajan LN, Sen SK (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta, 370, 89-93. https://doi.org/10.1016/j.cca.2006.01.019
  20. Nomura AM, Kolonel LN (1991). Prostate cancer: a current perspective. Epidemiol Rev, 13, 200-27.
  21. Ozbek E, Otunctemur A, Dursun M, et al (2014). The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev, 15, 4029-32. https://doi.org/10.7314/APJCP.2014.15.9.4029
  22. Pandeya DR, Mittal A, Sathian B, Bhatta B (2014). Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley. Asian Pac J Cancer Prev, 15, 1031-3. https://doi.org/10.7314/APJCP.2014.15.2.1031
  23. Parsons JK, Bergstrom J, Barrett CE (2008). Lipids, Lipoproteins and Risk of benign prostatic hyperplasia in communitydwelling Men. BJU Int, 101, 313-8. https://doi.org/10.1111/j.1464-410X.2007.07332.x
  24. Platz EA, Leitzmann MF, Visvanathan K, et al (2006). Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst, 98, 1819-25. https://doi.org/10.1093/jnci/djj499
  25. Prabhat P, Tewari R, Natu SM, et al (2010). Is central obesity, hyperinsulinemia, and dyslipidemia associated with highgrade prostate cancer? A descriptive cross-sectional study. Ind J Uro, 26, 502-6. https://doi.org/10.4103/0970-1591.74440
  26. Stephen JF, Brady JB (2005). Obesity and prostate cancer: a growing problem. Clin Cancer Res, 11, 6763-6. https://doi.org/10.1158/1078-0432.CCR-05-1305
  27. Tewari R, Prabhat P, Natu SM, et al (2011). Association of benign prostatic hyperplasia (BPH) with metabolic syndrome (MS) and its components: A growing dilemma. J Men's Health, 8, 66-71. https://doi.org/10.1016/j.jomh.2010.09.231
  28. Tewari R, Rajender S, Natu SM, et al (2012). Diet, obesity, and prostate health: are we missing the link? J Andro, 33, 763-76 https://doi.org/10.2164/jandrol.111.015578
  29. Tewari R, Rajender S, Natu SM, et al (2013). Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study. Cytokine, 10, 130-4.
  30. Wuermli L, Joerger M, Henz S, et al (2005). Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis, 8, 316-20. https://doi.org/10.1038/sj.pcan.4500834
  31. Zeigler-Johnson CM, Walker AH, Mancke B et al (2002). Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered, 54, 13-21. https://doi.org/10.1159/000066695
  32. Zhang Q, Sun LJ, Qi J, Yang ZG, Huang T (2014). Influence of adipocytokines and periprostatic adiposity measurement parameters on prostate cancer aggressiveness. Asian Pac J Cancer Prev, 15, 1879-83. https://doi.org/10.7314/APJCP.2014.15.4.1879
  33. Zucchetto A, Tavani A, Dal ML, et al (2005). A history of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes, 29, 798-803. https://doi.org/10.1038/sj.ijo.0802979

Cited by

  1. Investigating the Incidence of Prostate Cancer in Iran 2005-2008 using Bayesian Spatial Ecological Regression Models vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5917
  2. Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1827
  3. Rising Cancer Incidence and Role of the Evolving Diet in Kenya pp.1532-7914, 2019, https://doi.org/10.1080/01635581.2018.1542010